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cense.Abstract Aim of the work: The aim was to study the outcome characteristics of systemic lupus
erythematosus (SLE) in Egyptians according to the age at disease onset and gender.
Patients and methods: We studied 239 SLE patients (185 adult and 54 Juvenile onset) with a female
to male ratio of 9.39–1 and a mean age of 28.23 ± 8.91 years and disease duration of
5.45 ± 4.25 years. Full history taking, thorough clinical examination, laboratory and relevant
radiological investigations were performed. Disease activity was assessed using SLEDAI and
damage by SLICC. Renal biopsies were done in those with renal involvement.
Results: The clinical manifestations, disease activity and damage and laboratory investigations of
the SLE patients varied according to the age at disease onset and gender. The prevalence of damageSheikh Ali Youssif, Cairo,
225085372.
m (S.M. Fawzy).
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100 T.A. Gheita et al.was obviously increased in juvenile patients and higher in males. Growth failure, delayed puberty
and ﬁbromyalgia were present more in Juvenile-onset patients. Adult onset SLE patients had a sig-
niﬁcantly higher secondary Sjo¨gren syndrome especially in females. In the present study, there was a
2.5% mortality and the commonly involved kidneys were an important cause of death.
Conclusion: Measuring organ damage in SLE is important with special concern to juvenile-onset
patients to allow for designing new treatments that improve control of disease activity and minimize
the development of irreversible damage. The kidney appeared to be commonly involved, especially
in males, indicating the importance of regular screening for early and appropriate management.
 2011 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
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Although the highest prevalence of SLE is among women of
childbearing age, juvenile-onset SLE (J-SLE) represents 10–
20% of all SLE cases. Childhood-onset lupus patients display
some differences in their disease proﬁle and are associated with
higher disease severity, and a more-rapid damage accrual com-
pared with adult-onset SLE (a-SLE) [1,2]. Appropriate man-
agement is critically dependent upon the proper assessment
of disease activity and organ damage [3].
Better disease outcome can be achieved if the disease bur-
den is more precisely deﬁned and the diagnosis and treatment
algorithms are established [4]. In spite of the improved sur-
vival, new morbidities have emerged leading to altered out-
come patterns [5] and SLE continues to cause signiﬁcant
morbidity juveniles. A better recognition of the age-speciﬁc
manifestations and long-term complications is required to im-
prove its outcome [6]. Although the clinical presentation and
immunological ﬁndings are similar to those of adults, juvenile
SLE patients usually have a more severe disease at onset with
higher rates of organ damage and mortality [7,8]. As a result of
the increased life expectancy, SLE patients are faced with con-
siderable morbidity from disease activity, side effects of medi-
cations, and co-morbid conditions [9]. Disease activity and
organ damage at the baseline predict the latter. Careful mon-
itoring of SLE disease activity is of value and individually tai-
lored treatment is guided by the predictors of course and
outcome [10]. It is recommended that SLE outcome be as-
sessed in terms of disease activity and damage [11].
Variations in SLE clinical manifestations, serology and out-
comes have been also related to gender differences [12]. It has
been suggested that childhood SLE is not rare in Egypt and
Africa [13]. These associations have been retrospectively eval-
uated in SLE Egyptian children [14]. The juvenile onset SLE
patients as well as the male SLE patients represent important
subsets which are commonly overlooked and require special
attention. The objective of this work is to detect the prevalence
and pattern of clinical manifestations, organ damage and out-
come in adult Egyptian patients with juvenile and adult onset
SLE and comparing males to females, taking into consider-
ation the risk factors associated with damage.
2. Patients and methods
The study, descriptive and cross-sectional, included 239
Egyptian SLE patients fulﬁlling the updated ACR revised
criteria for the classiﬁcation of SLE [15]. The patients were
attending the Rheumatology Clinic in New Children Hospital
and the Rheumatology and Internal medicine out-patientClinics of Cairo University Hospitals as well as the Pediatric
outpatient of the National research centre, Cairo during 2010.
The patients were grouped according to the age at disease
onset, group 1 including the adult onset SLE (a-SLE) and
group 2 the juvenile-onset SLE (J-SLE) patients with the dis-
ease starting before the age of 16 years. All the patients had
the disease duration P6 months at study entry. Full history
taking, thorough clinical examination, laboratory and relevant
radiological investigations were performed for all the patients.
Disease activity was assessed using the Systemic Lupus Erythe-
matosus Disease Activity Index (SLEDAI) [16] while assess-
ment of organ damage was made using the Systemic Lupus
International Collaborating Clinics/ACR (SLICC/ACR) index
[17] and the pediatric version was used for the juvenile-onset
SLE patients [18]. The clinical manifestations are described
based on the SLEDAI and SLICC items.
Renal biopsies were done only in patients with renal
involvement and compromise, the specimens processed for
light microscopy and classiﬁed according to the 1982 modiﬁed
WHO morphologic classiﬁcation of lupus nephritis [19]. The
renal class was retrospectively considered in 116 patients
who had a biopsy performed during the year preceding the
study. The revised version of classiﬁcation criteria for
Sjo¨gren’s syndrome (SS) was considered for its diagnosis
[20]. Fibromyalgia syndrome was considered according to
the ACR criteria [21]. The study has been approved by local
ethics committee and it conforms to the standards currently
applied in Cairo University Teaching Hospitals.
Statistics. For statistical analysis the total group of patients
was divided in two subgroups according to the age at symp-
toms onset: Group I: adult onset SLE (a-SLE) (>16 years)
and Group II: juvenile onset Lupus (j-SLE) (616 years). They
were also analyzed according to gender (male-SLE vs. female-
SLE). Analysis of data was performed with a statistical pack-
age for the social sciences (SPSS) version 15. Data were pre-
sented as mean ± standard deviation and percentage. Mann–
Whitney test was used for analysis of two non-parametric
quantitative data. Correlation was performed by Spearman
correlation coefﬁcient. p value was considered signiﬁcant if
<0.05.
3. Results
3.1. Outcome of SLE patients according to the age at disease
onset
The study included 239 SLE patients. The a-SLE comprised of
185 patients and 54 J-SLE with the female/male ratio 9.39:1.
The ratio was less in J-SLE (6.71:1), being 10.56:1 in adult
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damage scores and clinical manifestations of the a-SLE and J-
SLE patients are shown in Tables 1–3, respectively. Growth
failure in 18 patients (33.33%) and delayed puberty in 8 pa-
tients (14.81%) were further considered in the 54 J-SLE pa-
tients’ damage.
The laboratory results of the studied SLE patients included
ESR 1st hour 53.39 ± 29.75 mmHg, hemoglobin level
10.86 ± 2.19 g%, WBC count 7.5 ± 4.1 · 103 mm3, platelet
count 310 ± 124.61 · 103 mm3, AST 31.91 ± 23.24 U/l,
ALT 28.41 ± 22.71 U/l, albumin 3.62 ± 0.66 g/dl, creatinine
0.76 ± 0.4 mg/dl, urea 35.76 ± 21.64 mg/dl and serum uric
acid 5.57 ± 2.45 mg/dl. There was no signiﬁcant difference
in these laboratory results according to the age at disease on-
set. However, the urine protein level in g/24 h (0.78 ± 1.12)Table 1 Demographic features of the adult and Juvenile-onset SLE
Characteristics of SLE patients (mean ± SD) All patients (239)
Age (years) 28.23 ± 8.91
Age at onset (years) 22.79 ± 8.87
Disease duration (years) 5.45 ± 4.25
Body Mass Index (BMI) 26.37 ± 4.41
Bold values are signiﬁcantly different at p< 0.05.
Table 2 Disease activity and damage index of the adult and Juven
Disease activity and damage (mean ± SD) All patients (239)
SLEDAI 11.5 ± 8.3
SLICC 2.55 ± 2.25
Bold values are signiﬁcantly different at p< 0.05.
Table 3 Clinical manifestations and associations of the adult and J
Clinical manifestations number (%) All patients (239)
Constitutional 158 (66.11)
Mucocutaneous 174 (72.8)
Arthritis 155 (64.85)
Hematological 175 (73.22)
Thrombocytopenia 29 (12.13)
Renal 150 (62.76)
Neuropsychiatric 89 (37.24)
Gastrointestinal 31 (12.97)
Cardiovascular 34 (14.23)
Pulmonary 67 (28.03)
Serositis 131 (54.81)
Peripheral vascular disease 20 (8.37)
DVT 44 (18.41)
Vertebral collapse 2 (0.84)
Avascular necrosis 10 (4.18)
Osteomyelitis 4 (1.67)
Ocular 17 (7.11)
Diabetes 10 (4.18)
APS 102 (42.68)
FMS 71 (29.71)
DVT: deep venous thrombosis; APS: antiphospholipid syndrome; FMS:was signiﬁcantly higher in adult SLE patients (0.88 ± 1.23 g/
24 h) compared to juvenile onset (0.47 ± 0.5 g/24 h). The com-
plement factor C3 was 0.69 ± 0.35 mg/dl while C4 was
0.24 ± 0.41 mg/dl. The anticardiolipin (ACL) IgG was
16.06 ± 9.81 IU/l and the ACL IgM 13.51 ± 6.85 IU/l, anti-
Ro 17 ± 14.06 U/ml and anti-La 12.38 ± 8.94 U/ml. The
antinuclear antibody (ANA) was positive in 223 patients
(93.31%) while the anti-double stranded DNA was positive
in 158 patients (66.11%). Again there was no difference of
signiﬁcance in these laboratory results according to the age
of disease onset.
All patients with renal involvement (62.76%) underwent re-
nal biopsy and according to the WHO classiﬁcation of lupus
nephritis the patients were classiﬁed as shown in Table 4.
Eleven patients had acute renal failure and another 10patients.
Adult-onset SLE (185) J-SLE (54) p value
30.62 ± 8.34 20.45 ± 5.7 0.000
25.92 ± 7.62 12.6 ± 3.15 0.000
4.7 ± 3.46 7.87 ± 5.52 0.000
26.81 ± 4.06 24.7 ± 5.29 0.058
ile-onset SLE patients.
Adult-onset SLE (185) J-SLE (54) p value
11.43 ± 8.22 11.35 ± 8.71 0.88
2.32 ± 2.13 3.2 ± 2.53 0.03
uvenile-onset SLE patients.
Adult-onset SLE (185) J-SLE (54)
127 (68.65) 31 (57.41)
138 (74.59) 36 (66.66)
120 (64.86) 35 (64.81)
132 (71.35) 43 (79.63)
19 (10.27) 10 (18.52)
111 (60) 39 (72.22)
68 (36.76) 21 (38.88)
25 (13.51) 6 (11.11)
23 (12.43) 11 (20.37)
47 (25.41) 20 (37.03)
100 (54.1) 31 (57.41)
16 (8.65) 4 (7.41)
40 (21.62) 4 (7.41)
2 (1.08) 0 (0)
8 (4.32) 2 (3.7)
3 (1.62) 1 (1.85)
14 (7.57) 3 (5.55)
9 (4.86) 1 (1.85)
92 (49.73) 10 (18.52)
50 (27.03) 21 (38.88)
ﬁbromyalgia syndrome.
Table 4 Renal biopsy class of the adult and Juvenile-onset
SLE patients.
Renal biopsy
number (%)
150 patients 111 patients
of a-SLE
39 patients
of J-SLE
Class 0 4 (2.67) 0 (0) 4 (10.26)
Class 1 78 (52) 63 (56.76) 15 (38.46)
Class 2 13 (8.67) 9 (8.11) 4 (10.26)
Class 3 18 (12) 10 (9.01) 8 (20.51)
Class 4 31 (20.67) 23 (20.72) 8 (20.51)
Class 5 5 (3.33) 5 (4.5) 0 (0)
Class 6 1 (0.67) 1 (0.9) 0 (0)
Table 5 Different lines of treatment used in all the SLE
patients.
Treatment regimen No. (%)
Corticosteroids only 61 (25.52)
Corticosteroids + azathioprine (Aza) 35 (14.64)
Corticosteroids + hydroxychloroquine (HCQ) 38 (15.9)
Corticosteroids + cyclophosphamide (Cyclo) 36 (15.1)
Corticosteroids + HCQ+Aza 23 (9.62)
Corticosteroids + Cyclo + HCQ+Aza 15 (6.28)
Corticosteroids + Cyclo + Aza 7 (2.93)
Corticosteroids + Cyclo + HCQ 6 (2.51)
Corticosteroids + mycophenolate mofetil 6 (2.51)
Not receiving any medications 12 (5.02)
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GFR <50%; 7 of them were on regular hemodialysis and
the other 3 had undergone successful renal transplantation.
Seizures were present in 56.18% of those with neuropsychiatric
manifestation, 33.7% had mood affection and cognitive
impairment, 14.61% had psychosis, 22.47% coma, 16.85% mi-
graine, and 5.62% had neuropathy and stroke. Mitral regurge
was found in 5 a-SLE and 6 J-SLE patients with associated tri-
cuspid regurge in 3 of them. Hypertension was present in 54
(29.19%) a-SLE and 8 (14.81%) J-SLE patients. Pulmonary
hypertension was present in 3 (5.55%); 1 a-SLE and 2 J-SLE
while cardiomyopathy occurred in 3.7% of J-SLE patients.
Pulmonary ﬁbrosis was present in 1 J-SLE patients. Intestinal
infarction was present in one a-SLE and another J-SLE pa-
tient, chronic peritonitis in one J-SLE, alopecia with scarring
in 10 a-SLE and 2 J-SLE, extensive panniculitis in 15 a-SLE
and 7 J-SLE and skin ulcers were present in 3 a-SLE and 2
J-SLE patients. None of the patients had any external genital
defect or malignancy. Dry eyes were symptomatic in 32.43%
a-SLE and 25.93% J-SLE and dry mouth in 21.08% and
11.11% while secondary SS was present in 17.3% and
11.11%, respectively.
The prevalence of damage was 75.14% in a-SLE and
85.19% in J-SLE patients with the majority having a low dam-
age index. The prevalence was higher in males (91.3%) com-
pared to females (75.93%). Hemolytic anemia was present in
26.78%, thrombocytopenia in 46 patients (19.25%) and leuco-
penia in 54 (22.59%) mostly a-SLE. Heavy proteinuria
P3.5 g/24 h was present in 3 a-SLE patients. The lipid proﬁle
was mildly altered and insigniﬁcantly different according to
age at disease onset or gender.
The SLICC signiﬁcantly negatively correlated with the age
at disease onset (r= 0.2, p = 0.002) and signiﬁcantly corre-
lated with the SLEDAI (p< 0.0001) and disease duration
(r= 0.23, p< 0.0001). The SLEDAI signiﬁcantly correlated
with the creatinine, urea, 24 h urine protein and steroid dose
(r= 0.15, p = 0.04; r = 0.27, p = 0.001; r = 0.25, p<
0.0001 and r= 0.3, p< 0.0001, respectively). While it nega-
tively correlated with albumin level (r= 0.49, p = 0.0001).
The steroid dose signiﬁcantly correlated with proteinuria
(r= 0.28, p< 0.0001) and negatively with C3 (r= 0.22,
p= 0.013). Anti-Ro and anti-La signiﬁcantly correlated with
the SLEDAI and SLICC (p< 0.0001). Furthermore, the
anti-cardiolipin IgG and IgM signiﬁcantly correlated with
the SLEDAI (r= 0.4, p = 0.007 and r = 0.51, p= 0.001).
The renal biopsy classes were comparable in the a-SLE and
J-SLE patients. Renal biopsy class signiﬁcantly correlated with
creatinine, 24 h urinary protein and uric acid (r= 0.32,p< 0.0001; r = 0.2, p = 0.005 and r = 0.38, p = 0.009,
respectively) and negatively correlated with C3 (r= 0.22,
p = 0.01).
The mean steroid dose used by all the patients was
19.83 ± 11.8 mg/day being slightly higher in a-SLE patients.
The different treatment regimens used for the patients at the
time of the study are shown in Table 5. Plasmapheresis was
performed in three patients as an additional therapy, 2 tried
IVIg therapy and oral anticoagulants was used by 45. Cyclo-
phosphamide was given to 42 (77.77%) J-SLE and 85
(45.95%) a-SLE patients.
3.2. Outcome of SLE patients according to the gender
Fig. 1 shows the mean SLICC/ACR damage index in the stud-
ied SLE patients. The biopsy classes tended to be higher in
male SLE patients. The mean steroid dose was signiﬁcantly
higher in the females (20.31 ± 11.99 mg/day) compared to
the males (15.45 ± 8.99 mg/day) (r= 0.07, p = 0.027).
Hypertension was present in 60 females (27.77%) and 4 males
(17.39%) with no gender differences.
Six of the patients (2.51%) who were included in the study
died later on during the following year, four were J-SLE and
the other two were a-SLE. They all had lupus nephritis and
were on hemodialysis, two had uncontrolled hypertension with
heart failure and another died from pulmonary edema; they
were four females and two males. Mortality was due to the
underlying renal disease and the superimposed complications.4. Discussion
In the present study, the SLICCwas signiﬁcantly higher in the J-
SLE patients being higher in males with the majority of all SLE
patients having a low damage index. In harmony with the pres-
ent results are the ﬁndings that disease onset is more severe in
childhood-onset patients [22,23] with a higher and earlier risk
of damage being more in males [24]. In a-SLE studies, damage
was present in 44.8% [25] and 31% of patients [26]. The rate
of damage in this studywas higher than that observed in compa-
rable studies which could be acknowledged to themany races in-
cluded, while the current study included only Egyptians, and the
differences in number of studied patients.Moreover, themortal-
ity rate was higher in those studies compared to that of the pres-
ent study whichmay explain the increasedmorbidity and rate of
damage in the patients included in this study. The increased
damage in J-SLE was attributed to renal and musculoskeletal
Figure 1 The mean SLICC/ACR damage index in the adult and juvenile onset SLE patients and their gender differences.
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with the age at disease onset in the present study,which could ex-
plain the poorer outcome, more severe disease expression and
more aggressive therapy observed in younger children which is
similar to the ﬁndings of Al-Mayouf and Al-Sonbul [24]. In a-
SLE patients, gender inﬂuences the clinical expression of disease
independent of age, while both gender and age do not affect the
overall damage score [28]. After years of follow up, 88% of J-
SLE patients continued to have a high SLEDAI with 42% of
them having a mean SLICC of 1.62 ± 2.1 [7]. The SLEDAI
and SLICC signiﬁcantly correlated in this study. However, it
was concluded that both remain independent SLE outcome
measures [29].
The female tomale ratiowas 9.39:1being 6.86:1 in J-SLEcom-
pared to 10.56:1 in a-SLE. In other studies on J-SLE patients it
was 4.6:1 [30], 5.85:1 [24] and 4.7:1 [31] whichmay be attributable
to ethnic differences. Furthermore, the ratio in a-SLE was higher
which ensures the importance of hormonal factors in the clinical
expression of the disease. The mean disease duration was
7.87 ± 5.52 years. The prevalence of damage was higher in J-
SLE (83.64%) compared to a-SLE patients (75.14%) and inmale
SLE patients compared to females. In other studies, organ dam-
agewasobserved in 50–60%ofpatients [9,32], in aBrazilian study
it was 32% [33] and in another study 61% [34]. Conversely, there
was no signiﬁcant gender difference in themajor organmanifesta-
tion in a-SLE patients [26]. Although the renal manifestations
were more in J-SLE, the 24 h proteinuria was signiﬁcantly higher
ina-SLEwhich suggests that renal involvement is not the only fac-
tor responsible for the higher damage index andmortality seen in
J-SLE. Active disease especially renal at presentation and over
time [22] and damage at follow-up were more in J-SLE [31]. The
most frequent systems involved were the mucocutaneous, renal,
musculoskeletal and neuropsychiatric [32,35].
Variations in SLE clinical manifestations and outcomes are
related to gender differences. In this study, serositis, renal
involvement and SLICC were higher in males. Similarly, in a
study on adult SLE patients, males were more likely to have
serositis, renal involvement with end-stage renal disease and
a poorer outcome as the SLICC was 2.7 ± 2.7 vs 1.0 ± 1.6
in females [12]. Young SLE women had more Raynauds, pho-
tosensitivity and mucosal ulcers. However, there were no sig-
niﬁcant differences regarding the clinical and laboratory
features, disease activity or damage index scores between the
two genders [28,30].In J-SLE patients, arthritis occurred in 63.63%, mucocuta-
neous manifestations in 65.45%, renal involvement in 70.6%
and CNS disease in 38.18%. In similar studies on J-SLE, the
most common clinical manifestations were arthritis (67%),
malar rash (66%), nephritis (55%), and CNS disease (27%)
[31]. Renal disease and SLEDAI were higher in J-SLE [22]
contributing to the higher mortality rate [36]. In the present
study, acute renal failure was present in 11 patients and an-
other 10 passed into ESRD. In another study, lupus nephritis
in J-SLE was present in 51% and acute renal failure in 20.08%
[37]. Similar to our ﬁndings, in J-SLE patients the hematolog-
ical manifestations and anti-DNA antibodies were more fre-
quent [38]. Pulmonary involvement was seen in 27.92% of
cases being higher in J-SLE. Conversely, it was low and with
no radiographic evidence of ILD in J-SLE given the higher fre-
quency in a-SLE [39]. Growth failure was present in 32.73%
and delayed puberty in 14.55% of J-SLE as 76.36% were
receiving cyclophosphamide and ovarian reserve was signiﬁ-
cantly reduced [7]. Renal damage and growth failure were ob-
served most frequently in J-SLE [40]. Lupus nephritis has been
described as the most serious complication of SLE and the
strongest predictor of poor outcome. While the incidence of
childhood SLE is relatively low, renal involvement appears
to be more common and severe [41].
Fibromyalgia syndrome was present in 29.58% being high-
er in J-SLE patients. The prevalence of FMS in SLE is consis-
tently 20–25% [42] and this association may pose a diagnostic
dilemma [43]. The SS in the present study was present in a
higher number of a-SLE females. Anti-Ro and anti-La signif-
icantly correlated with the SLEDAI and SLICC during the
study. In accordance was the presence of SS in 14% of SLE pa-
tients especially older females [44]. Secondary SS is as high as
90% and a new subset has been suggested in late-onset patients
with anti-SSA/Ro antibodies [45,46].
In the present study, the kidney was the commonly involved
and an important cause of death. The mortality rate was high-
er in J-SLE patients and also in males. Early damage is associ-
ated with a higher mortality rate [47]. Renal disease and
mortality were signiﬁcantly higher in SLE men [12,48].
In conclusion, measuring organ damage in SLE is impor-
tant with special concern for juvenile-onset and male patients
thus allowing for designing new treatments aimed at improving
the control of disease activity and minimizing the development
of irreversible damage. There is a high rate of disease activity
104 T.A. Gheita et al.and damage in Egyptian SLE patients being more common in
J-SLE. The kidney appeared to be commonly involved,
especially in males, indicating the importance of regular
screening for early and appropriate management.
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